公开(公告)号：US11530213B2

公开(公告)日：2022-12-20

申请号：US17071311

申请日：2020-10-15

Applicant: NOVARTIS AG

Inventor： Guillaume Barbe ,  Gregory Raymond Bebernitz ,  Sicong Geng ,  Hatice Belgin Gulgeze Efthymiou ,  Lv Liao ,  Fupeng Ma ,  Ruowei Mo ,  David Thomas Parker ,  Yunshan Peng ,  Stefan Peukert ,  Nichola Smith ,  Ken Yamada ,  Kayo Yasoshima

IPC: A61P9/00 ,  A61P9/06 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6561

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20140134262A1

公开(公告)日：2014-05-15

申请号：US14128877

申请日：2012-07-06

Applicant: NOVARTIS AG

Inventor： Yoshie Arai ,  Margaret Elizabeth Brousseau ,  Jessie Gu ,  Tomoko Hayashi ,  Hironobu Mitani ,  Muneto Mogi ,  Kazuhiko Nonomura ,  Ken Yamada

IPC: A61K31/5377 ,  A61K31/4709 ,  A61K31/506 ,  A61K45/06 ,  A61K31/44 ,  A61K31/55 ,  A61K31/421 ,  A61K31/444 ,  A61K31/4439

CPC classification number: A61K31/421 ,  A61K31/41 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06

Abstract: The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

Abstract translation: 本发明提供式I化合物：用于治疗，改善和/或预防与甘油三酯水平高的受试者中CETP活性相关的疾病和病症，例如动脉粥样硬化和血脂异常; 其中R1，X1，R7，R5，C，L和p在本文中定义。 本发明还提供了用于治疗，改善和/或预防与甘油三酯水平高的受试者中CETP活性如动脉粥样硬化和血脂异常相关的疾病和病症的药理活性剂的组合。

公开(公告)号：US10266531B2

公开(公告)日：2019-04-23

申请号：US15788248

申请日：2017-10-19

Applicant: NOVARTIS AG

Inventor： Guillaume Barbe ,  Gregory Raymond Bebernitz ,  Sicong Geng ,  Hatice Belgin Gulgeze Efthymiou ,  Lv Liao ,  Fupeng Ma ,  Ruowei Mo ,  David Thomas Parker ,  Yunshan Peng ,  Stefan Peukert ,  Ken Yamada ,  Kayo Yasoshima

IPC: C07D487/04 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6561 ,  A61P9/06

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20180153861A1

公开(公告)日：2018-06-07

申请号：US15831545

申请日：2017-12-05

Applicant: NOVARTIS AG

Inventor： Yoshie ARAI ,  Margaret Elizabeth Brosseau ,  Jessie Gu ,  Tomoko Hayashi ,  Hironobu Mitani ,  Muneto Mogi ,  Kazuhiko Nonomura ,  Ken Yamada

IPC: A61K31/421 ,  A61K31/55 ,  A61K31/41 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/44 ,  A61K31/505 ,  A61K45/06 ,  A61K31/5377

CPC classification number: A61K31/421 ,  A61K31/41 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06

Abstract: The present invention provides a compound of Formula I for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.